Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control

Launched by MAYO CLINIC · May 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether using personal continuous glucose monitors (CGMs) during a hospital stay can help manage diabetes better. The goal is to see if the data from these devices can guide insulin treatment, helping to keep blood sugar levels stable and reduce the chances of having episodes of low or high blood sugar. The researchers also want to check if this approach makes both patients and hospital staff happier with how blood sugar is monitored and treated.

To participate in this trial, you need to be at least 18 years old and have diabetes or high blood sugar that requires insulin treatment while in the hospital. You should also be using a CGM at home and bring it with you to the hospital. Participants must be admitted for more than 48 hours but should not be in an intensive care unit or have certain health issues like liver disease or diabetes complications. If you join the study, you can expect to have your glucose levels monitored closely, and your insulin treatment adjusted based on real-time data from your CGM. This trial is not yet recruiting, so keep an eye out for updates if you're interested!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with ages above 18 years old at the time of informed consent.
• • 2. Male or female
• • 3. Admitted to non-ICU setting in brick-and-mortar medical and surgical ward or admitted to Advanced Care at Home Program.
• • 4. Admitted under observation or inpatient status.
• • 5. Expected to remain in the hospital for more than 48 hours.
• • 6. Patients that are using a transcutaneous or implantable real time CGM as outpatient and are bringing it to the hospital.
• • 7. Patients with diagnosis of diabetes mellitus or hyperglycemia requiring treatment with SQ insulin in the hospital either with multiple daily injections or subcutaneous infusion of insulin via insulin pump.
• Exclusion Criteria:
• • 1. Participants unable to provide informed medical consent.
• • 2. Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU.
• • 3. Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state)
• • 4. Patients with a diagnosis of liver cirrhosis.
• • 5. Patients with a diagnosis of ESRD or Acute Renal Failure on hemodialysis or peritoneal dialysis.
• • 6. Patients with planned MRI or surgical procedure. Enrollment is possible after MRI or surgery.
• • 7. Participants with allergy to medical grade adhesive or medical tape.
• • 8. Participants who are pregnant, wanting to become pregnant, or nursing during study period.
• • 9. Participants using Medtronic and Dexcom sensors and taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
• • 10. Participants using Dexcom sensors and taking hydroxyurea.
• • 11. Participants using Libre sensors and taking over 500 mg of ascorbic acid.
• • 12. Patients using Eversense sensors and taking tetracycline type of antibiotics.
• • 13. Participants actively enrolled in other studies addressing their CGM use unless express permission is obtained from prior study research team principal investigator or co-principal investigator.